PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.
"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.
Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.
The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv
PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.
"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.
Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.
The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read morePharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read moreWe are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more